Control measures for assessing compliance in long-term Potentially Reduced Risk Product switching studies

Mike McEwan1, Nathan Gale1, George Hardie1, Max Scherer2, Nikola Pluym3, James K. Ebajemito3, Oscar M. Camacho1, Allen Griffiths1, James Murphy1 and Christopher J. Proctor1

1British American Tobacco (Investments) Limited, Research and Development, Regents Park Road, Southampton, SO15 8TL, U.K.
2ABF GmbH, Semmelweisstraße 5, D-82152 Planegg, Germany

Poster 5-213 at SRNT Annual Meeting, 11th-14th March 2020, New Orleans, USA

Introduction

Recently, clinical studies have shown reductions in exposure to tobacco smoke toxicants when smokers of conventional cigarettes switch to tobacco heating products (THP). These are generally short-term confined studies where compliance is well controlled. However, to investigate whether these reductions in exposure to cigarette toxicants can translate to smoking-related health risks, long-term studies are required. In this case, ambulatory studies are often the preferred approach, with subjects visiting the clinic at specific timepoints. Therefore, the potential for non-compliance, where the subject smokes conventional cigarettes and not the assigned THP, is high.

To address this, in a 12-month study examining health effect indicators when smokers switch to using the glo THP in the UK (ISRCTN81075760), we have incorporated a biomarker of compliance (BoC), the haemoglobin adduct of acrylonitrile, N-(2-cyanoethyl)valine (CEVal). This paper presents the results of a planned interim analysis of CEVal after 90 days.

Aim

To demonstrate the utility of CEVal as a biomarker for monitoring compliance in the 12-month study examining health effect indicators in the glo THP and nicotine cessation arms

Background

A schematic for the 12-month study is shown in Figure 1. This is an ambulatory study where subjects will go about their business as normal between study visits. Measures have been placed in the study to try to monitor compliance generally using subject diaries to record combustible cigarette usage in the glo THP switching and the nicotine cessation arms. As an additional measure, CEVal was analysed in blood samples taken at the clinic visits.

CEVal has been used as a control measure in other clinical studies. Noad et al.1 investigated dietary docosahexaenoic acid (DHA, long-chain omega 3) and soy protein effects on cholesterol and blood pressure. Compliance was also monitored using plasma DHA and urinary isoflavones. The rationale for CEVal selection is described in Figure 2 and Figure 3.

Table 1: Categorisation of subjects using CEVal levels2

<table>
<thead>
<tr>
<th>Category</th>
<th>Day 90</th>
<th>Day 180</th>
<th>Day 360</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highly Likely Smoking</td>
<td>&gt;164 pmol/g Hb</td>
<td>&gt;112 pmol/g Hb</td>
<td>&gt;78 pmol/g Hb</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potential Dual Use</td>
<td>78 - 164 pmol/g Hb</td>
<td>54 - 112 pmol/g Hb</td>
<td>35 - 78 pmol/g Hb</td>
</tr>
<tr>
<td>Potential Solus Use</td>
<td>&lt;78 pmol/g Hb</td>
<td>&lt;54 pmol/g Hb</td>
<td>&lt;35 pmol/g Hb</td>
</tr>
</tbody>
</table>

Results

To demonstrate the utility of CEVal as a biomarker for monitoring compliance in the 12-month study examining health effect indicators in the glo THP and nicotine cessation arms

As shown in Figure 6, on average levels of CEVal clearly are reduced in the glo and smoking cessation groups. Whereas, subjects in the continue to smoke arm show very little change in CEVal levels over 90 days. In the glo switching arm there were 74 subjects in total, 2 of which were in the non-compliant category and 10 in the dual-use category. This leaves 62 subjects in the compliant category.

For the cessation arm there were a total of 132 subjects with 3 continuing to smoke at similar levels prior to the study and 19 subjects who were smoking occasionally. This leaves a total of 110 subjects in the cessation arm in the compliant category.

Conclusions

This study shows that monitoring CEVal in a switching study, where subjects switch to the glo THP or cease smoking completely, is an effective method for measuring compliance. Further work however, is required to refine the thresholds set for categorising continuing to smoke and dual-product use.

References

5. Camacho et al. Contemporary Clinical Trials Communications 2020; 17:168025

Figure 2: Requirements for BoC in a tobacco context

Figure 3: Formation of CEVal Hb adducts

Figure 4: The glo tobacco heating product.

Figure 5: CEVal levels measured by Sheppard et al.4

Categorisation of subjects using CEVal levels

Based on data on CEVal levels from a previous study by Sheppard et al.4 (Figure 5) threshold levels for CEVal were set for the 12-month study to categorise subjects that smoked at around the same level as prior to the study, subjects that either used both glo and continued to smoke (dual use) or subjects in the cessation group that continue to smoke occasionally and finally subjects that were compliant (Table 1).